



Patent  
207/145

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: ) Group Art Unit: To be Assigned  
ANDREW C. HIATT and FLOYD ROSE )  
Serial No. 08/300,484 ) Examiner: To be Assigned  
Filed: September 1, 1994 )  
For: ENZYME CATALYZED TEMPLATE- )  
INDEPENDENT CREATION OF )  
PHOSPHODIESTER BONDS USING )  
PROTECTED NUCLEOTIDES )

MAR 15 1994

STATEMENT UNDER 37 C.F.R. § 1.821 (F)

Best Available Copy

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821 (e), (f) and (g), or § 1.825 (d) and (b) respectively, are the same.

Respectfully submitted,

LYON & LYON

By: Jeffrey W. Guise  
Jeffrey W. Guise  
Registration No. 34,613

First Interstate World Center  
633 West Fifth Street  
Suite 4700  
Los Angeles, CA 90071  
(213) 489-1600

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231

Kim Arnold-Cabeller  
Name of Person Mailing Paper


KC Cabeller  
Signature of Person Mailing Paper

Feb 6, 1995

Date of Deposit

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
7. Other: \_\_\_\_\_

**Applicant must provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123  
 For CRF submission help, call (703) 308-4212  
 For PatentIn software help, call (703) 308-6856

**Please return a copy of this notice with your response.**

Best Available Copy